Infiniti Intelligence Hourly Briefing — Oct 13, 2026 · 7:39 PM ET

Confidentiality questions for pharma partners

Prediction markets are revealing a potential gap in pharmaceutical vendor confidentiality agreements, according to Pharmaceutical Executive’s Oct. 13 coverage. The report frames the issue as a concern raised by experts.

Contract research organizations, labs and other outside partners often receive early access to trial and FDA data, according to the outlet’s summary. That places the confidentiality question beyond pharmaceutical companies’ own staff.

The concern centers on whether vendor confidentiality arrangements adequately address prediction markets. The available material does not establish that any particular company, contractor or market participant misused information.

The source page text was unavailable, and the supplied summary is incomplete. It provides no specific contract provisions, named experts or documented trading cases with which to assess the scope of the reported gap.

What it means for prediction markets

• Information access is the central issue: Outside pharmaceutical partners may see trial and FDA data early, making their confidentiality obligations relevant to markets tied to those outcomes.
• The evidence is limited: The supplied material supports a reported concern about confidentiality agreements—not a finding of improper trading or a demonstrated effect on market prices.

A full NHL slate takes the lead

All 32 NHL teams are on tonight’s Frozen Frenzy schedule, with MacKinnon carrying the highest listed anytime-goal-scorer price at 45.86c, according to the supplied headline for the Oct 13, 2026 update.

The edition, published at 7:39 PM ET, shifts to live sports after a 15-minute period without a significant new platform headline. It also changes categories from the previous three editions, according to the supplied summary.

A price snapshot with limited context

Action Network is the linked outlet for coverage of the Frozen Frenzy anytime-goal-scorer slate. However, the supplied page extract contains site formatting and promotional material rather than substantive reporting, leaving no additional player prices or matchup analysis to establish comparisons.

MacKinnon’s 45.86c listing is therefore the central pricing detail available. The supplied material does not identify the platform, contract settlement terms or earlier prices, so it does not establish whether that figure reflects a recent move.

What it means for prediction markets

• Relative pricing is the main signal: MacKinnon is identified as the most expensive anytime scorer, but the absence of other prices prevents measuring his lead over the field.
• The slate is broad; the evidence is narrow: All 32 teams feature tonight, but the material supplies only one player-level price.
• Do not confuse a snapshot with momentum: Without price history or trading data, the 45.86c figure cannot establish a trend or a change in market conviction.